Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia
Open Access
- 1 October 2003
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 123 (2) , 243-252
- https://doi.org/10.1046/j.1365-2141.2003.04610.x
Abstract
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.Keywords
This publication has 35 references indexed in Scilit:
- Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 TrialBlood, 2003
- Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemiaBlood, 2002
- Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemiaBlood, 2002
- Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcriptsLeukemia, 2002
- Advances in the immunological monitoring of childhood acute lymphoblastic leukaemiaBest Practice & Research Clinical Haematology, 2002
- Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemiaLeukemia, 2002
- Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratificationBlood, 2001
- A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer GroupBlood, 2001
- A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trialBritish Journal of Haematology, 1999
- Prediction of Relapse of Pediatric Acute Myeloid Leukemia by Use of Multidimensional Flow CytometryJNCI Journal of the National Cancer Institute, 1996